The Mouse Model Allows Sharma To Test The Compound In Both Late And Early Stages Of The Disease To See If It She Can Prevent Diabetic Retinopathy From Happening, She Said.

After battling diabetes for nearly 40 years, Lowe has developed diabetic retinopathy, a consequence of uncontrolled diabetes that can damage small blood vessels in the eye and is the leading cause of blindness among working-age adults. A researcher across campus from the clinic is looking at a different way of potentially blocking the inflammation that can lead to that damage through a potential new drug. Dr. Shruti Sharma of the Center for Biotechnology and Genomic Medicine has a $1.5 million grant from the National Eye Institute to look at basic research into blocking inflammation among epithelial cells in light-sensing retina in the eye, Sharma is looking at a well-known agent in inflammation called interleukin-6 that can affect those cells even though they lack the receptor normally needed for such interaction, an effect called trans-signaling. While that effect had been known for a while it is not something that researchers had focused on in the past, she said. Sharma is looking at an experimental drug that in her early work seems to have blocked that type of action in those cells, using it both in the lab in human cells in the same kind of environment that is there in the eye and in a mouse model of diabetes. The hope is to prevent the barrier disruption to the cells that can cause them to become leaky and create inflammation, an early hallmark of the disease. The mouse model allows Sharma to test the compound in both late and early stages of the disease to see if it she can prevent diabetic retinopathy from happening, she said. Separately, the compound is being tested in human clinical trials in rheumatoid arthritis, which is also promising, Sharma said. Im more excited because I am re-purposing this drug, she said.

For the original version including any supplementary images or video, visit http://www.washingtontimes.com/news/2017/jan/1/new-drug-might-help-with-diabetes-related-blindnes/?utm_source=RSS_Feed&utm_medium=RSS

If.ou have any questions at any time after cataract surgery, call your eye doctor for advice. no dataSome patients report double vision in the affected eye although this symptom seems to decrease or disappear entirely as the cataracts grows. This procedure leaves sufficient capsule to hold the lens in place, but removes enough to allow light to pass directly through to the retina. Some babies are born with cataracts or develop them in childhood, often in both eyes. People with nuclear sclerotic or brunescent cataracts often notice a reduction of vision . A Closer Look At Strategies Of Cataracts – Guidance To The ViewThe skin and the lens have the same embryological origin and so can be affected by similar diseases. 18 Those with atomic dermatitis and eczema occasionally develop shield ulcers cataracts. Often there are only mild vision changes. Mayo Clinic, Rochester, Finn. Prevalence and risk factors for cataract in diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study, report no. 17.

Leave a Reply

Your email address will not be published. Required fields are marked *